Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.
Pipeline Report 2021: COVID-19 Edition
Annual Reports, AstraZeneca, Bayer, BioNTech, BNT162b2 (Pfizer and BioNTech), CanSino Biologics, Clinical Trials, Clover Biopharmaceuticals, Clover Biopharmaceuticals, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, CureVac, Eli Lilly, February 2021, Gamaleya Research Institute, Gilead, GlaxoSmithKline, Immunology Companies, Inovio Pharmaceuticals, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Med Ad News, Merck, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Novavax, Oxford University, Pfizer, R&D, Sanofi, Sinopharm, Sinovac, Special Reports, Sputnik V vaccine, The Lancet, Therapeutics, Top 10 Pipelines, Top 10 Pipelines To Watch, Vaccine Companies, Valneva, Vir BiotechnologyAs the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
Med Ad News talked to Bill Dreitlein – Senior Director, Pipeline & Drug Surveillance at OptumRx – about some of the most promising new molecular entities in the industry pipeline and challenges the FDA has faced during the COVID-19 pandemic.
Todd Wills, Managing Director, Consulting Services at CAS, talked to Med Ad News about what COVID-19 has taught us about pharmaceutical R&D; insights and predictions on future drug approval trends; and other topics.
The promise of personalized medicine, with its potential for treatments tailored to individual patients’ genomic footprints to generate better outcomes, has long tantalized the life sciences industry. Now, advanced imaging analytics and the extraction of high dimensional data from medical images, called radiomics, is emerging as the other side of the personalization coin.
Kevin Jacob, Head of Imaging at Illingworth Research Group (a SYNEOS HEALTH company), touches upon the myriad potential applications of medical photography and explore key considerations for use of these highly technical imaging techniques in clinical trials.
Top 10 Pipelines To Watch
Acquisitions, Analysts, Annual Reports, Blockbuster Deals, Blockbusters, Business, Clinical Trials, Deals, Dengue, Department of Health and Human Services (HHS), Dermatology, Diffuse Large B-Cell Lymphoma (DLBCL), EMA, European Commission, European Medicines Agency (EMA), FDA, FDA/Regulatory, February 2020, Future Blockbusters, Hemophilia A, Hospital-Acquired Bacterial Pneumonia, Issue Archives, Licensing, Natural Killer Cells (NK Cells), New Drug Applications, New Molecular Entities, NMEs, Oncology, Potential Blockbusters, Priority Review, Priority Review Status, Product Pipelines, R&D, Rare Diseases, Senate Panel, Special Reports, Top 10 Pipelines, Top 10 Pipelines To Watch, VaccinesAs pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Oncology Innovation
Annual Reports, Antibody-Drug Conjugates (ADCs), Biomarkers, Bladder Cancer, BRCA mutation, Breast Cancer, Clinical Trials, FDA/Regulatory, February 2020, Issue Archives, Non-Small Cell Lung Cancer (NSCLC), Oncology, Pancreatic Cancer, R&D, Targeted Therapies, Thyroid Cancer, Top 10 Pipelines To WatchOncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.
MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.
Top 10 Pipelines To Watch: 2019 Annual Report
Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, BRCA Gene, BRCA mutation, Breakthrough Therapy Designation, Business, Cancer, CAR-T Therapy, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, RNA Interference (RNAi), Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare DiseasesThe return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.